AstraZeneca cholesterol drug Crestor drove the company’s third-quarter financials forward as generic competition significantly affected other medications.

Although revenues fell 2% to approximately $8.2bn, Crestor reported a sales increase of 14% to $1.66bn, with US sales rising 20% and total prescriptions up 3%.

The company also benefitted from strong performances from the antipsychotic Seroquel and Seroquel XR, with sales rising 4% and 24% respectively.

AstraZeneca’s oncology portfolio fell significantly, however, with a number of patent expiries impacting on drug performance. Arimidex sales fell 44% to $176m, whereas Casodex declined by 9%.

AstraZeneca chief executive David Brennan said: "We have delivered a third-quarter revenue and core earnings performance in line with our expectations, against the backdrop of anticipated generic competition and government price interventions."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.